A story in the Aug. 14, 2001, issue of BioWorld Today should hve reported that Cerus Corp. has 15.6 million shares outstanding and about $147 million in cash, cash equivalents and short-term investments.
An article in the same issue should have reported that the average wholesale cost to hospitals for Scios Inc.s product, Natrecor, will be $456 per bottle.
Editors Note: The correction has been made in BioWorld Online.